Abstract Body

Background

Quantification of CD4 T helper cells is important for tracking disease progression and monitoring opportunistic infections in people living with HIV (PLHIV). Discontinuation of two point of care (POC) CD4 tests, the PIMA CD4 (Abbott, IL, USA) and FACSPresto (Becton Dickinson Biosciences, San Jose CA), has created an unmet need for remote CD4 enumeration. We investigated CD4 counting off dried blood spot (DBS) specimens using novel epigenetic qPCR to potentially fill gaps in global health needs. 

Methods

Residual K3EDTA specimens from PLHIV (n=150) received for routine immunophenotyping, by PanLeucogating (PLG) technology performed on an AQUIOS flow cytometer (Beckman Coulter, Brea, CA), at the National Health Laboratory Service in Johannesburg, South Africa, were spotted (~70µl) onto Whatman 903 Protein Saver Cards (Merck, Darmstadt, Germany) and cobas® Plasma Separation Cards (140µl) (PSC, Roche Molecular, Pleasonton, CA). DBS and PSC (6mm punched) spots were manually extracted for DNA using the i.Mune CD4 Prep. This was followed by novel epigenetic quantification of CD4+ T-cells using the i.Mune CD4 Amp that included a GAPDH internal control (Epimune Diagnostics, Berlin, Germany). Real-time PCR was conducted on a QuantStudio 7 (Thermo Fisher Scientific, USA) and Cycle threshold (Ct) values converted into absolute CD4 counts using a data analysis tool. 

Results

The median PLG CD4 count of the specimens was 176 cells/µl (5-1361cells/µl), and the concordance correlation with the i.Mune CD4 qPCR absolute count off a DBS showed a moderate strength of agreement Pc=0.91 (95% confidence interval [CI] 0.88 to 0.94). The mean bias was -28.40 cells/µl with a broad scatter (standard deviation [SD] of the bias =120.62cells/µl), and overall agreement of 102% percentage similarity.  A 5.9% (3/51) misclassification rate was observed at CD4<100 cells/µl and 12.5% (10/80) at CD4<200 cells/µl. A qPCR invalid rate was reported as 4.7% (7/150). The overall performance of the cobas® PSC i.Mune CD4 qPCR showed greater variance (Pc=0.16 [95% CI 0.054 to 0.26]) and requires a modified extraction protocol. 

Conclusions

In the absence of CD4 POCT and PLG CD4 immunophenotyping requiring testing within 5 days post venesection, the i.Mune CD4 could provide an alternative option off DBS collected from remote settings. qPCR also has the advantage of being performed on existing laboratory platforms and infrastructure.